Kevin Etzkorn brings over 12 years of venture capital, operational, and technical management experience to the Fund.
Prior to joining Heron, Mr. Etzkorn was a Principal at CID Capital, a venture capital and private equity firm...
Read more about Kevin Etzkorn.
See the entire
NeoChord is a venture backed medical device company that has developed a proprietary device which allows mitral valve repair to be performed on a beating heart through a 2 to 3 inch incision between the ribs in patients with severe mitral valve regurgitation. In contrast, most mitral valve repair procedures are performed through a 3 to 10 inch chest incision...
View Our Portfolio
AirXpanders Announces First Commercial U.S. Procedure for AeroForm® Tissue Expander System for Breast Reconstruction
January 18, 2017
US FDA grants de novo clearance to AirXpanders' AeroForm Tissue Expander System for breast reconstruction
December 26, 2016
First Patient Treated in U.S. Randomized Trial of NeoChord’s, Off-Pump, Minimally Invasive Repair for Degenerative Mitral Regurgitation
November 9, 2016